Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $4
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $7 to $4.
Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $7 to $4.